ArticleCancer communications (London, England)2019

Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience.

Jianhong Peng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.